Publisher
Springer International Publishing
Reference19 articles.
1. Capitanio U, Montorsi F. Seminar renal cancer. Lancet. 2016;387:894–906. Available at:. https://doi.org/10.1016/S0140-6736(15)00046-X.
2. Psutka SP, Chang SL, Cahn D, et al. Reassessing the role of cytoreductive nephrectomy for metastatic renal cell carcinoma in 2019. Am Soc Clin Oncol Educ Book. 2019;345(23):1655–9.
3. Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy followed by interferon Alfa-2b compared with interferon Alfa-2b alone for metastatic renal-cell cancer. N Engl J Med. 2001;345(23):1655–9.
4. Mickisch GHJ, Garin A, Van Poppel H, et al. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet. 2001;358(9286):966–70.
5. Flanigan RC, Mickisch G, Sylvester R, et al. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol. 2004;171(3):1071–6.